247 related articles for article (PubMed ID: 22780212)
1. EPHA3 as a novel therapeutic target in the hematological malignancies.
Keane N; Freeman C; Swords R; Giles FJ
Expert Rev Hematol; 2012 Jun; 5(3):325-40. PubMed ID: 22780212
[TBL] [Abstract][Full Text] [Related]
2. Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics.
London M; Gallo E
Mol Biol Rep; 2020 Jul; 47(7):5523-5533. PubMed ID: 32621117
[TBL] [Abstract][Full Text] [Related]
3. The Eph/Ephrin family in cancer metastasis: communication at the service of invasion.
Kandouz M
Cancer Metastasis Rev; 2012 Jun; 31(1-2):353-73. PubMed ID: 22549394
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors.
Charmsaz S; Scott AM; Boyd AW
Exp Hematol; 2017 Oct; 54():31-39. PubMed ID: 28751189
[TBL] [Abstract][Full Text] [Related]
5. Expression of Eph receptors and their ligands, ephrins, during lipopolysaccharide fever in rats.
Ivanov AI; Steiner AA; Scheck AC; Romanovsky AA
Physiol Genomics; 2005 Apr; 21(2):152-60. PubMed ID: 15671251
[TBL] [Abstract][Full Text] [Related]
6. Copy number variations of EphA3 are associated with multiple types of hematologic malignancies.
Guan M; Liu L; Zhao X; Wu Q; Yu B; Shao Y; Yang H; Fu X; Wan J; Zhang W
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):50-3. PubMed ID: 21454190
[TBL] [Abstract][Full Text] [Related]
7. Emerging targets for hematological malignancies.
Cilloni D; Frassoni F; Saglio G
Curr Opin Drug Discov Devel; 2010 Sep; 13(5):548-58. PubMed ID: 20812146
[TBL] [Abstract][Full Text] [Related]
8. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
[TBL] [Abstract][Full Text] [Related]
9. The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies.
Milella M; Kornblau SM; Andreeff M
Rev Clin Exp Hematol; 2003 Jun; 7(2):160-90. PubMed ID: 14763161
[TBL] [Abstract][Full Text] [Related]
10. Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies.
Fulda S
Leukemia; 2012 Jun; 26(6):1155-65. PubMed ID: 22230799
[TBL] [Abstract][Full Text] [Related]
11. CD44 in hematological neoplasias.
Hertweck MK; Erdfelder F; Kreuzer KA
Ann Hematol; 2011 May; 90(5):493-508. PubMed ID: 21258793
[TBL] [Abstract][Full Text] [Related]
12. [Hematologic malignancies /pediatric malignancies-current status of molecular target therapy for hematologic cancer].
Usui N
Gan To Kagaku Ryoho; 2010 May; 37(5):805. PubMed ID: 20524247
[No Abstract] [Full Text] [Related]
13. Eph-modulated cell morphology, adhesion and motility in carcinogenesis.
Wimmer-Kleikamp SH; Lackmann M
IUBMB Life; 2005 Jun; 57(6):421-31. PubMed ID: 16012051
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies as therapeutics in human malignancies.
Pandey M; Mahadevan D
Future Oncol; 2014 Mar; 10(4):609-36. PubMed ID: 24754592
[TBL] [Abstract][Full Text] [Related]
15. The EphA3 receptor is expressed in a subset of rhabdomyosarcoma cell lines and suppresses cell adhesion and migration.
Clifford N; Smith LM; Powell J; Gattenlöhner S; Marx A; O'Connor R
J Cell Biochem; 2008 Dec; 105(5):1250-9. PubMed ID: 18814179
[TBL] [Abstract][Full Text] [Related]
16. The role of ephrins and Eph receptors in cancer.
Surawska H; Ma PC; Salgia R
Cytokine Growth Factor Rev; 2004 Dec; 15(6):419-33. PubMed ID: 15561600
[TBL] [Abstract][Full Text] [Related]
17. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.
Sankhala K; Giles FJ
Expert Rev Hematol; 2009 Aug; 2(4):399-414. PubMed ID: 21082945
[TBL] [Abstract][Full Text] [Related]
18. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment.
Vail ME; Murone C; Tan A; Hii L; Abebe D; Janes PW; Lee FT; Baer M; Palath V; Bebbington C; Yarranton G; Llerena C; Garic S; Abramson D; Cartwright G; Scott AM; Lackmann M
Cancer Res; 2014 Aug; 74(16):4470-81. PubMed ID: 25125683
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance-related microRNAs in hematological malignancies: translating basic evidence into therapeutic strategies.
Xie L; Jing R; Qi J; Lin Z; Ju S
Blood Rev; 2015 Jan; 29(1):33-44. PubMed ID: 25263425
[TBL] [Abstract][Full Text] [Related]
20. Targeting Wnt signaling pseudokinases in hematological cancers.
Karvonen H; Perttilä R; Niininen W; Barker H; Ungureanu D
Eur J Haematol; 2018 Oct; 101(4):457-465. PubMed ID: 29989208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]